Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease

Neuroscience Letters

Volumn 522, Issue 1, 2012, Pages 30-35

  Belin, Andrea Carmine ^a   Ran, Caroline ^a   Anvret, Anna ^a   Paddock, Silvia ^a   Westerlund, Marie ^a   Håkansson, Anna ^b   Nissbrandt, Hans ^b   Söderkvist, Peter ^c   Dizdar, Nil ^c,d   Ahmadi, Ahmad ^c   Anvret, Maria ^e,f   Willows, Thomas ^e   Sydow, Olof ^e   Galter, Dagmar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Linkage disequilibrium; Lipid peroxidation; Pesticide

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; GLUTAMINE; LEUCINE; METHIONINE;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 84863781249     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.06.007     Document Type: Article

References (34)

1. Abecasis G.R., Cookson W.O. GOLD - graphical overview of linkage disequilibrium. Bioinformatics 2000, 16:182-183.
2. Ahmed Z., Ravandi A., Maguire G.F., Emili A., Draganov D., La Du B.N., Kuksis A., Connelly P.W. Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochemical and Biophysical Research Communications 2002, 290:391-396.
3. Akhmedova S.N., Yakimovsky A.K., Schwartz E.I. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. Journal of the Neurological Sciences 2001, 184:179-182.
4. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. Journal of Clinical Investigation 1998, 101:1581-1590.
5. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
6. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 2001, 11:77-84.
7. Carmine Belin A., Galter D. S18Y, UCH-L1 and Parkinson's disease. European Neurological Review 2008, 3:41-44.
8. Carmine A., Buervenich S., Sydow O., Anvret M., Olson L. Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Movement Disorders 2002, 17:764-766.
9. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics 1994, 7:180-184.
10. Cowan J., Sinton C.M., Varley A.W., Wians F.H., Haley R.W., Munford R.S. Gene therapy to prevent organophosphate intoxication. Toxicology and Applied Pharmacology 2001, 173:1-6.
11. Daniel S.E., Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. Journal of Neural Transmission 1993, 39:165-172.
12. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics 1996, 14:334-336.
13. Dick F.D. Parkinson's disease and pesticide exposures. British Medical Bulletin 2006, 79-80:219-231.
14. Do C.B., Tung J.Y., Dorfman E., Kiefer A.K., Drabant E.M., Francke U., Mountain J.L., Goldman S.M., Tanner C.M., Langston J.W., Wojcicki A., Eriksson N. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genetics 2011, 7:e1002141.
15. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Human Heredity 2008, 66:87-98.
16. Erlich P.M., Lunetta K.L., Cupples L.A., Abraham C.R., Green R.C., Baldwin C.T., Farrer L.A. Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease. Neurobiology of Aging 2012, 33:e7-e23.
17. Erlich P.M., Lunetta K.L., Cupples L.A., Huyck M., Green R.C., Baldwin C.T., Farrer L.A. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Human Molecular Genetics 2006, 15:77-85.
18. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biology and Medicine 1991, 11:81-128.
19. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. Journal of Clinical Investigation 1997, 99:62-66.
20. Le Couteur D.G., McLean A.J., Taylor M.C., Woodham B.L., Board P.G., Pesticides Parkinson's disease. Biomedicine and Pharmacotherapy 1999, 53:122-130.
21. Leviev I., James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20:516-521.
22. Leviev I., Negro F., James R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arteriosclerosis, Thrombosis, and Vascular Biology 1997, 17:2935-2939.
23. Liu Y., Fallon L., Lashuel H.A., Liu Z., Lansbury P.T. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002, 111:209-218.
24. Mackness B., Durrington P.N., Mackness M.I. The paraoxonase gene family and coronary heart disease. Current Opinion in Lipidology 2002, 13:357-362.
25. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., Miller J.E., Boulton A.J., Durrington P.N. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998, 139:341-349.
26. Manthripragada A.D., Costello S., Cockburn M.G., Bronstein J.M., Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010, 21:87-94.
27. Michelakakis H., Xiromerisiou G., Dardiotis E., Bozi M., Vassilatis D., Kountra P.M., Patramani G., Moraitou M., Papadimitriou D., Stamboulis E., Stefanis L., Zintzaras E., Hadjigeorgiou G.M. Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. Movement Disorders 2012, 27:400-405.
28. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics 2007, 81:559-575.
29. Ronaghi M., Uhlen M., Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998, 281:363-365.
30. Taylor M.C., Le Couteur D.G., Mellick G.D., Board P.G. Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. Journal of Neural Transmission 2000, 107:979-983.
31. Wilkinson K.D., Lee K.M., Deshpande S., Duerksen-Hughes P., Boss J.M., Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989, 246:670-673.
32. Wingo T.S., Rosen A., Cutler D.J., Lah J.J., Levey A.I. Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases. Neurobiology of Aging 2010.
33. Zintzaras E. The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Statistical Applications in Genetics and Molecular Biology 2010, 9. (Article 21).
34. Zintzaras E., Hadjigeorgiou G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: a meta-analysis. Journal of Human Genetics 2004, 49:474-481.